Mwandishi:
Mhariri:
Imeboreshwa;
ULY CLINIC
ULY CLINIC
27 Oktoba 2026, 13:25:33
Sickle cell disease: hydroxyurea therapy
Sickle cell disease: hydroxyurea therapy
Chanzo: National Sickle Cell Disease Management Guidelines, Ministry of Health Tanzania. Toleo: 2nd edition, June 2026. Mwongozo wa Taifa (supporting guideline). The STG 2026 article "Sickle Cell Disease (SCD) Treatment" remains the main reference.
How hydroxyurea helps
Increases haemoglobin F (HbF) levels.
Increases steady-state haemoglobin.
Lowers white blood cells and platelets, which reduces the chronic inflammation of SCD.
Who should receive hydroxyurea
Everyone with SCD from 9 months of age, and all adults with SCD.
Once started, continue hydroxyurea for life unless it is not tolerated.
Do not start hydroxyurea during an episode of severe illness; wait until the patient is stable. Continue it during hospital admissions and illness in patients already taking it.
Tests before starting hydroxyurea
Full blood picture: absolute neutrophil count (ANC) above 1,500/µL, platelets above 100,000/µL, Hb above 6 g/dL.
If Hb is below 6 g/dL, do a reticulocyte count. Do not start hydroxyurea if Hb is below 6 g/dL AND the absolute reticulocyte count (ARC) is below 100,000/µL.
Serum creatinine (should be within the normal range).
Serum ALT (should not be more than twice the upper limit of normal).
Total and direct bilirubin.
Urine pregnancy test in women.
HPLC to measure HbF. If HPLC cannot be done, prescribe hydroxyurea anyway; a high baseline HbF should not change the decision to start.
Table 1. Starting dose of hydroxyurea (national guideline)
Group | Starting dose |
Adults | 15 mg/kg/day (round up to the nearest 500 mg). With chronic kidney disease: 5–10 mg/kg/day. |
Infants and children below 15 years | 20 mg/kg/day. Where only 500 mg capsules are available, calculate the weekly dose in capsules and spread the capsules through the week. |
Worked example (national guideline): a 10 kg child at 20 mg/kg/day = 200 mg/day = 1,400 mg/week, which is about 3 capsules of 500 mg per week: give 1 capsule on Monday, Wednesday and Friday.
Counsel males and females of reproductive age to use contraception while taking hydroxyurea.
Monitoring
Table 2. Review and full blood picture schedule on hydroxyurea (national guideline)
Period | Review visit and full blood picture |
First month | Every 2 weeks |
Next 3 months | Every month |
After that | Every 3 months if counts have been stable for the first 4 months; monthly if counts fluctuate |
At each visit: take a history and examine the patient, check adherence to hydroxyurea and other medicines, weigh the patient every 3 months (or when indicated) and adjust the dose to the weight. Check serum creatinine, urea and ALT every 6 months.
Stop hydroxyurea if ANC is below 1.0 × 10⁹/L, OR Hb is below 6 g/dL with ARC below 80 × 10⁹/L, OR platelets are below 80 × 10⁹/L.
Dose escalation
Adjust the dose to keep ANC between 1.5 and 2.5 × 10⁹/L.
Increase the dose by 2.5–5 mg/kg/day every 3 months if ANC is above 1.5 × 10⁹/L, Hb is 6 g/dL or more and platelets are above 80 × 10⁹/L.
Escalate up to a maximum of 30 mg/kg/day in patients with abnormal TCD or stroke, or if ANC stays above 1.5 × 10⁹/L. Check adherence before each increase; increase by 2.5–5 mg/kg/day with at least 2 months between increases; after each increase, check the full blood picture on the starting schedule.
Dose adjustment for toxicity
If one or more counts fall into the toxic range (ANC below 1 × 10⁹/L or platelets below 50 × 10⁹/L), stop hydroxyurea and do a full blood picture every 2 weeks.
Restart at the same dose if the affected count recovers within 2 weeks.
Reduce the dose by 2.5 mg/kg if the toxicity lasts more than 2 weeks or there was earlier toxicity at the current dose.
Then check the full blood picture on the starting schedule.
Note: the national guideline gives two platelet limits: stop if platelets are below 80 × 10⁹/L (review rule) and toxic range below 50 × 10⁹/L (toxicity rule). Both are printed as shown.
Response to treatment
The clinical response may take 3–6 months. Give a 6-month trial at the maximum tolerated dose before calling it treatment failure, whether due to poor adherence or lack of response.
Hydroxyurea raises haemoglobin, HbF and MCV. Monitor RBC, MCV and HbF for a laboratory response; HbF above 20% clearly improves the clinical condition. A lack of rise in MCV and/or HbF is not a reason to stop therapy.
Side effects
Myelotoxicity (low blood counts).
Mouth ulcers.
Skin toxicity: rashes and hyperpigmentation.
Hydroxyurea in pregnancy (new in the national guideline)
Stop hydroxyurea during the first trimester if this is safe for the mother; maternal safety takes priority over fetal safety.
Continue hydroxyurea after the first trimester and throughout pregnancy.
All decisions should involve the pregnant woman, an obstetrician and an SCD specialist.
⚠ Tofauti na STG 2026: STG 2026 says to stop hydroxyurea at least 3 months before conception (in both men and women) and to stop it during pregnancy and breastfeeding. The national SCD guideline (June 2026) instead stops it in the first trimester if safe and continues it after the first trimester, with a joint decision by the woman, obstetrician and SCD specialist. Discuss each pregnant woman with a specialist.
⚠ Tofauti na STG 2026 (dosing): STG 2026 gives the same starting doses (adults 15 mg/kg/day, children 20 mg/kg/day); the escalation steps, maximum dose and monitoring schedule above come from the national guideline.
Imeandikwa:
27 Oktoba 2026, 13:23:58
Rejea za mada:
1. Ministry of Health Tanzania. National Sickle Cell Disease Management Guidelines, 2nd edition. June 2026. Part IV, section 3: Hydroxyurea therapy (pages 29–32).
2. Ministry of Health Tanzania. STG-NEMLIT 7th edition, 2026: Sickle Cell Disease (SCD) Treatment; Sickle Cell Disease in Pregnancy.
